https://www.live-feeds.com/feed/moderna-s-cancer-vaccine-success-doesn-t-live-up-to-early-hypeContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/moderna-s-cancer-vaccine-success-doesn-t-live-up-to-early-hypehttps://www.live-feeds.com/feed/moderna-s-cancer-vaccine-success-doesn-t-live-up-to-early-hype#u157780Tue, 27 Oct 2026 10:10:30 +0000Moderna and Merck released Phase 3 trial data for their personalized mRNA cancer vaccine, intismeran autogene, combined with the immunotherapy drug Keytruda. The vaccine cut the risk of melanoma recurrence and death by forty-two percent, which barely cleared analysts expectations but fell short of the forty-nine percent reduction seen in earlier Phase 2 testing. Following an earlier data leak, shares of both companies fell as investors digested the trial results. Doctors also raised concerns regarding the treatment's high cost and complex manufacturing process.Why it mattersThe experiment